Fasciola hepatica: The therapeutic potential of a worm secretome

Mark Robinson; John Dalton; Bronwyn O'Brien; Sheila Donnelly

doi:10.1016/j.ijpara.2012.11.004

Fasciola hepatica: The therapeutic potential of a worm secretome

Mark Robinson, John Dalton, Bronwyn O'Brien, Sheila Donnelly

School of Biological Sciences

Research output: Contribution to journal › Literature review

32 Citations (Scopus)

372 Downloads (Pure)

Abstract

The success of helminth parasites is partly related to their ability to modulate host immune responses towards an anti-inflammatory/regulatory phenotype. This ability resides with the molecules contained in the secretome of various helminths that have been shown to interact with host immune cells and influence their function. Consequently, there exists a unique opportunity to exploit these molecules for the prophylactic and therapeutic treatment of human pro- and auto-inflammatory disorders (for example septic shock, transplant rejection and autoimmune disease). In this review, we describe the mechanisms used by the trematode parasite, Fasciola hepatica, to modulate the immune responses of its host and discuss the potent immune-modulatory effects of three individual molecules within the secretome; namely cathepsin L1, peroxiredoxin and helminth defence molecule. With a focus on the requirements from industry, we discuss the strategies by which these molecules may be clinically developed to control human immune responses in a way that is conducive to the prevention of immune-mediated diseases.

Original language	English
Pages (from-to)	283–291
Number of pages	9
Journal	International Journal for Parasitology
Volume	43
Issue number	3-4
DOIs	https://doi.org/10.1016/j.ijpara.2012.11.004
Publication status	Published - Mar 2013

Bibliographical note

The work contributing to this review was supported by National Health and Medical Research Council of Australia Grants APP1010197 and APP513111. J.P.D is supported by a Tier 1 Canada Research Chair and a grant from the National Science and Engineering Council (NSERC) Canada, and is a member of the European Union FP7-funded PARAVAC consortium.

ASJC Scopus subject areas

Parasitology
Infectious Diseases

Access to Document

10.1016/j.ijpara.2012.11.004

Fasciola hepatica: The therapeutic potential of a worm secretome
NOTICE: this is the author’s version of a work that was accepted for publication in International Journal for Parasitology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in International Journal for Parasitology, [VOL 43, ISSUE 2-3, 2013]
Accepted author manuscript, 727 KB

Fingerprint Dive into the research topics of 'Fasciola hepatica: The therapeutic potential of a worm secretome'. Together they form a unique fingerprint.

Cite this

Robinson, M., Dalton, J., O'Brien, B., & Donnelly, S. (2013). Fasciola hepatica: The therapeutic potential of a worm secretome. International Journal for Parasitology, 43(3-4), 283–291. https://doi.org/10.1016/j.ijpara.2012.11.004

@article{93950919a06f47e78c558153291561d0,

title = "Fasciola hepatica: The therapeutic potential of a worm secretome",

abstract = "The success of helminth parasites is partly related to their ability to modulate host immune responses towards an anti-inflammatory/regulatory phenotype. This ability resides with the molecules contained in the secretome of various helminths that have been shown to interact with host immune cells and influence their function. Consequently, there exists a unique opportunity to exploit these molecules for the prophylactic and therapeutic treatment of human pro- and auto-inflammatory disorders (for example septic shock, transplant rejection and autoimmune disease). In this review, we describe the mechanisms used by the trematode parasite, Fasciola hepatica, to modulate the immune responses of its host and discuss the potent immune-modulatory effects of three individual molecules within the secretome; namely cathepsin L1, peroxiredoxin and helminth defence molecule. With a focus on the requirements from industry, we discuss the strategies by which these molecules may be clinically developed to control human immune responses in a way that is conducive to the prevention of immune-mediated diseases.",

author = "Mark Robinson and John Dalton and Bronwyn O'Brien and Sheila Donnelly",

note = "The work contributing to this review was supported by National Health and Medical Research Council of Australia Grants APP1010197 and APP513111. J.P.D is supported by a Tier 1 Canada Research Chair and a grant from the National Science and Engineering Council (NSERC) Canada, and is a member of the European Union FP7-funded PARAVAC consortium.",

year = "2013",

month = mar,

doi = "10.1016/j.ijpara.2012.11.004",

language = "English",

volume = "43",

pages = "283–291",

journal = "International Journal for Parasitology",

issn = "0020-7519",

publisher = "Elsevier Limited",

number = "3-4",

}

TY - JOUR

T1 - Fasciola hepatica

T2 - The therapeutic potential of a worm secretome

AU - Robinson, Mark

AU - Dalton, John

AU - O'Brien, Bronwyn

AU - Donnelly, Sheila

N1 - The work contributing to this review was supported by National Health and Medical Research Council of Australia Grants APP1010197 and APP513111. J.P.D is supported by a Tier 1 Canada Research Chair and a grant from the National Science and Engineering Council (NSERC) Canada, and is a member of the European Union FP7-funded PARAVAC consortium.

PY - 2013/3

Y1 - 2013/3

N2 - The success of helminth parasites is partly related to their ability to modulate host immune responses towards an anti-inflammatory/regulatory phenotype. This ability resides with the molecules contained in the secretome of various helminths that have been shown to interact with host immune cells and influence their function. Consequently, there exists a unique opportunity to exploit these molecules for the prophylactic and therapeutic treatment of human pro- and auto-inflammatory disorders (for example septic shock, transplant rejection and autoimmune disease). In this review, we describe the mechanisms used by the trematode parasite, Fasciola hepatica, to modulate the immune responses of its host and discuss the potent immune-modulatory effects of three individual molecules within the secretome; namely cathepsin L1, peroxiredoxin and helminth defence molecule. With a focus on the requirements from industry, we discuss the strategies by which these molecules may be clinically developed to control human immune responses in a way that is conducive to the prevention of immune-mediated diseases.

AB - The success of helminth parasites is partly related to their ability to modulate host immune responses towards an anti-inflammatory/regulatory phenotype. This ability resides with the molecules contained in the secretome of various helminths that have been shown to interact with host immune cells and influence their function. Consequently, there exists a unique opportunity to exploit these molecules for the prophylactic and therapeutic treatment of human pro- and auto-inflammatory disorders (for example septic shock, transplant rejection and autoimmune disease). In this review, we describe the mechanisms used by the trematode parasite, Fasciola hepatica, to modulate the immune responses of its host and discuss the potent immune-modulatory effects of three individual molecules within the secretome; namely cathepsin L1, peroxiredoxin and helminth defence molecule. With a focus on the requirements from industry, we discuss the strategies by which these molecules may be clinically developed to control human immune responses in a way that is conducive to the prevention of immune-mediated diseases.

U2 - 10.1016/j.ijpara.2012.11.004

DO - 10.1016/j.ijpara.2012.11.004

M3 - Literature review

C2 - 23220126

VL - 43

SP - 283

EP - 291

JO - International Journal for Parasitology

JF - International Journal for Parasitology

SN - 0020-7519

IS - 3-4

ER -